Articles from 20/20 Biolabs Inc.

20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities

Recently Nasdaq-Listed Company Introduces Longevity Blood Test Integrating Inflammatory Biomarkers, Dietary Habits, and Curated Scientific Research to Deliver Personalized Health Insights

By 20/20 Biolabs Inc. · Via GlobeNewswire · February 25, 2026

20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time

By 20/20 Biolabs Inc. · Via GlobeNewswire · February 20, 2026

20/20 BioLabs Debuts Trading on Nasdaq Under Ticker Symbol "AIDX" Following 3 Consecutive Years of Sales Growth

Company Ready to Scale Growth through OneTest™ AI-Powered Blood Tests for Cancer and Longevity

By 20/20 Biolabs Inc. · Via GlobeNewswire · February 19, 2026